Quick Answer
Skye Bioscience, Inc. reported Cash and Equivalents of $5.88 million for fiscal year 2025.
Skye Bioscience, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.88M | -91.4% |
| 2024 | $68.42M | +5345.1% |
| 2023 | $1.26M | -32.2% |
| 2018 | $1.85M | +613.0% |
| 2017 | $260.0K | +301.0% |
| 2016 | $64.8K | -98.0% |
| 2015 | $3.22M | +1453.7% |
| 2014 | $207.3K | -79.8% |
| 2014 | $1.03M | +1864.2% |
| 2013 | $52.2K | +97.6% |
| 2012 | $26.4K | +89.8% |
| 2011 | $13.9K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $18.44M | -72.6% | -22.6% |
| June 30, 2025 | $23.84M | -67.8% | -48.6% |
| March 31, 2025 | $46.42M | -44.3% | -32.1% |
| December 31, 2024 | $68.42M | +5345.1% | +1.5% |
| September 30, 2024 | $67.41M | +1215.0% | -9.1% |
| June 30, 2024 | $74.12M | +13292.7% | -11.1% |
| March 31, 2024 | $83.34M | +3023.0% | +6533.2% |
| December 31, 2023 | $1.26M | +1.0% | -75.5% |
- Skye Bioscience, Inc. showed a decrease of -91.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Skye Bioscience, Inc.’s cash and equivalents has grown by 42177.5% (from $13.9 thousand to $5.88 million).
- The most recent figure is from Skye Bioscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: